A Non-Randomized, Open Label, Study to Assess Hepatitis C Viral Kinetics in Predicting the Clinical Response in Patients With Hepatitis C Infection Coinfected With HIV-1 Treated With Peginterferon Alpha-2b and Ribavirin.
Phase of Trial: Phase II
Latest Information Update: 12 Nov 2014
At a glance
- Drugs Peginterferon alfa-2b (Primary) ; Ribavirin (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms HEPCPR
- 31 Aug 2018 Biomarkers information updated
- 16 May 2012 Additional trial acronym (HEPCPR) identified as reported by ClinicalTrials.gov.
- 16 May 2012 Actual patient number is 40 according to ClinicalTrials.gov.